Patents by Inventor Thomas J. McMurry
Thomas J. McMurry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115744Abstract: This disclosure relates to compounds of Formula IV: for fibrin imaging, wherein the compounds comprise an imaging or therapeutic radioisotope.Type: ApplicationFiled: October 23, 2020Publication date: April 11, 2024Inventors: Peter Caravan, Thomas J. McMurry, Richard J. Looby
-
Patent number: 10301358Abstract: Compounds and methods for imaging and/or assessing collagen are described. The compounds can include collagen binding peptides.Type: GrantFiled: June 29, 2016Date of Patent: May 28, 2019Assignee: Collagen Medical, LLCInventors: Richard J. Looby, Peter D. Caravan, Thomas J. McMurry
-
Publication number: 20160376319Abstract: Compounds and methods for imaging and/or assessing collagen are described. The compounds can include collagen binding peptides.Type: ApplicationFiled: June 29, 2016Publication date: December 29, 2016Inventors: Richard J. Looby, Peter D. Caravan, Thomas J. McMurry
-
Patent number: 9096646Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CXCR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow transplantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.Type: GrantFiled: November 4, 2009Date of Patent: August 4, 2015Assignee: Anchor Therapeutics, Inc.Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
-
Publication number: 20150011466Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: January 9, 2013Publication date: January 8, 2015Inventors: Thomas J. McMurry, Richard J. Looby
-
Publication number: 20130210709Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.Type: ApplicationFiled: November 4, 2009Publication date: August 15, 2013Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
-
Patent number: 8394356Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: August 29, 2011Date of Patent: March 12, 2013Assignee: Lantheus Medical Imaging, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Publication number: 20120107249Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: ApplicationFiled: August 29, 2011Publication date: May 3, 2012Applicant: LANTHEUS MEDICAL IMAGING, INC.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Publication number: 20120028888Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: November 4, 2009Publication date: February 2, 2012Inventors: Jay Janz, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20110300167Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function.Type: ApplicationFiled: November 4, 2009Publication date: December 8, 2011Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic
-
Publication number: 20110301087Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor for corticotrophin releasing hormone (or factor) receptor 1, also known as the CRF1, CRHR1, CRFR1, CRHR, CRF-R. The CRF1 receptor compounds are derived from the intracellular loops and domains of CRF1 receptor. The invention also relates to the use of these CRF1 receptor compounds and pharmaceutical compositions comprising the CRF1 receptor compounds in the treatment of diseases and conditions associated with CRF1 receptor modulation, such as inflammatory bowel disease (peripherally acting), irritable bowel syndrome (IBS), stress response (colonic motor activity), anxiety, sleep disorder, addictive behavior, acute and chronic neurodegeneration, preterm labor and pain.Type: ApplicationFiled: November 4, 2009Publication date: December 8, 2011Inventors: Edward McBride, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20110294738Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.Type: ApplicationFiled: November 4, 2009Publication date: December 1, 2011Inventors: Yong Ren, Athan Kuliopulos, Thomas J. McMurry
-
Patent number: 8017105Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: June 22, 2006Date of Patent: September 13, 2011Assignee: Lantheus Medical Imaging, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7927581Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: GrantFiled: April 4, 2005Date of Patent: April 19, 2011Assignee: Factor 1A, LLCInventors: Zhaoda Zhang, John C. Amedio, Peter D. Caravan, Stephane Dumas, Andrew Kolodziej, Thomas J. McMurry
-
Patent number: 7238341Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: GrantFiled: February 25, 2004Date of Patent: July 3, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Zhaoda Zhang, John C. Amedio, Peter D. Caravan, Stephane Dumas, Andrew Kolodziej, Thomas J. McMurry
-
Patent number: 7229606Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 12, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7186797Abstract: The present invention relates to compounds and methods for synthesizing compounds wherein the compounds exhibit extended circulating half-life in the blood. The increase in circulating half-life is achieved by conjugating polypeptides to binding groups that exhibit high affinity for human serum albumin.Type: GrantFiled: August 9, 2002Date of Patent: March 6, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Theodore R. West, Thomas J McMurry, Stephane Dumas, Andrew Kolodziej
-
Patent number: 7147837Abstract: The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.Type: GrantFiled: January 16, 2004Date of Patent: December 12, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Randall B. Lauffer, Thomas J. McMurry, Stephen O. Dunham, Daniel M. Scott, David J. Parmelee, Stéphane Dumas
-
Patent number: 7060250Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 13, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7011815Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 30, 2003Date of Patent: March 14, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer